|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the measurement of HBV RNA prior to PEG-IFN-based therapy could identify patients with high probability of MVR.
|
31446638 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In contrast, in HBV several retrospective studies yielded conflicting results of the association of IL28B with PEG-IFN-induced treatment response.
|
26284971 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In lamivudine-naive patients, abatement of HBV DNA<10(3) copies/ml by pretreatment with PEG-IFN-alpha2a completely prevents the emergence of YMDD mutants after 24 months of lamivudine monotherapy.
|
20032538 |
2009 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In summary, our study suggests that HBV precore protein, specifically the p22 form, impedes JAK-STAT signaling to help the virus evade the host innate immune response and, thus, causes resistance to IFN therapy.<b>IMPORTANCE</b> Chronic hepatitis B virus (HBV) infection continues to be a major global health concern, and patients who fail to mount an efficient immune response to clear the virus will develop a life-long chronic infection that can progress to chronic active hepatitis, cirrhosis, and primary hepatocellular carcinoma.
|
31019054 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In the cell-culture-based HBV infection models, the sensitivity of HBV to IFN-α in hepatocytes is determined more by the cell-intrinsic IFN response than by viral genotype, and improvement of the IFN response in HepG2-NTCP cells promotes the efficacy of IFN-α against HBV.(Hepatology 2018;67:1237-1252).
|
29059468 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, 74 patients with chronic HBV infection who had virological responses to 180 μg/week Peg-IFNα-2a treatment were included; 38 (20 and 18 HBeAg positive and negative, respectively) of these patients were treated with 245 mg/day TDF, and 36 (20 and 16 HBeAg positive and negative, respectively) were treated with 0.5 mg/day ETV upon relapse after initial treatment discontinuation.
|
30963812 |
2019 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In vitro IFN-λ1 treatment of Hep3B and Huh7 human hepatoma cell lines increased MHC class I expression, activated JAK-STAT signaling pathways, induced IFN-stimulated gene expression, and inhibited hepatitis B surface antigen (HBsAg) expression.
|
24769671 |
2014 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intrahepatic mRNA levels of type-I interferon (IFN) receptor genes have been shown to correlate with the clinical efficacy of IFN therapy in patients with chronic hepatitis C. Recently, co-infection by serologically-silent hepatitis B virus (HBV) has been assumed to be associated with the poor IFN response in patients with chronic hepatitis C. The aim of this study was to investigate the relationship between the co-infection of serologically-silent HBV and type-I IFN receptor gene expression in the liver of patients with chronic hepatitis C. The intrahepatic mRNA levels of IFNAR2, one of the two subunits of the type-I IFN receptor, were quantified and compared with both the prevalence of HBV DNA and the hepatitis C virus (HCV) genotype in 45 patients with chronic hepatitis C, who were negative for hepatitis B surface antigen.
|
11170061 |
2001 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knockdown of FN expression significantly inhibited HBV DNA replication and protein synthesis through activating endogenous IFN-α production.
|
27023403 |
2016 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No significant differences were observed among groups for HBeAg seroconversion (PEG-IFN alfa-2a+placebo, 36.3%; PEG-IFN alfa-2a+ETV, 29.5%; and PEG-IFN alfa-2a+ADV, 27.4%), HBeAg loss (37.4%, 32.2%, and 28.6%, respectively) or change in hepatitis B surface antigen (HBsAg) levels from baseline (-0.56 IU/mL, -0.60 IU/mL, and -0.41 IU/mL, respectively).
|
29456079 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that OAS gene variations may play an important role in response to IFN-α and provide a novel strategy for the resolution of HBV infection.
|
21277331 |
2011 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study aimed to identify the host single nucleotide polymorphisms (SNPs) that predict IFN response in hepatitis B patients.
|
12447867 |
2002 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study was intended to evaluate HBV expression in liver biopsies taken an average of two years after completion of IFN-a therapy in 10 children with serological markers of persistent HBV infection.
|
11782686 |
2002 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
PEG-IFN-alfa 2b 1.5 microg/kg/wk was superior to IFN-alfa 2b in decreasing mean serum hepatitis C RNA ( P < .05 at week 12).
|
15952104 |
2005 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Since hepatitis B virus (HBV) genotype is an important predictor of response to PEG-IFN, determination of HBV genotype is essential in patients in whom sustained off-treatment response is pursued.
|
19187869 |
2008 |
|
Hepatitis B
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Single nucleotide polymorphisms and variant expression of some interferon (IFN) genes in individuals with chronic hepatitis B virus (HBV) infection might be related to higher viral load and disease complications.
|
27101083 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Standard treatment in HBV infection includes IFN-α, nucleoside, or nucleotide analogs, which has direct antiviral activity and immune modulatory capacities.
|
28450868 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting IFNα to the liver may be a strategy to increase its efficacy locally and may increase efficacy of IFNα-based therapy of HBV infection.
|
28709686 |
2017 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hepatitis B serological markers and viral loads were tested every 3 months until 1 year after stopping Peg-IFN therapy.
|
25835020 |
2015 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of the study is to investigate whether SNPs in JAK1 were associated with outcomes of HBV infection and response to IFNα therapy.
|
22901011 |
2012 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the influence of hepatitis B virus (HBV) genotypes on serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative patients treated with pegylated interferon-alpha2a (PEG-IFN-alpha2a).
|
20032548 |
2009 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The biochemical and virological responses to combined PEG-IFN and RBV therapy might be similar in CHC patients with or without occult HBV infection.
|
19817959 |
2010 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR.
|
27793564 |
2016 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
The content of HBV DNA in the supernatant of co-cultivation of HepG2.2.15 cells and PBMCs without stimulated materials was higher than that stimulated by HBcAg and IL-18 at various concentrations of HBcAg and IL-18 together with IL-12/IFN-alpha 1b.
|
15138116 |
2004 |